Why Are Altimmune Shares Trading Lower Wednesday?
Why Are Altimmune Shares Trading Lower Wednesday?
Altimmune, Inc. (NASDAQ:ALT) shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the company's chief financial officer.
納斯達克的altimmune股票價格出現明顯下跌，因爲該公司首席財務官理查德 · 艾森施塔特意外離世。
What To Know: Eisenstadt's sudden death has deeply saddened Altimmune, with CEO Vipin K. Garg highlighting his contributions and personal qualities that endeared him to colleagues.
要知道：艾森施塔特的意外去世讓Altimmune深感悲痛，首席執行官Vipin K.Garg強調他的貢獻和個人素質讓他深得同事們的喜愛。
In response to Eisenstadt's passing, Altimmune's finance and accounting functions are temporarily being managed by the existing team while the company initiates a search for his replacement. This transition period aims to maintain stability amid the loss of a key executive.
爲了應對艾森施塔特的離世，Altimmune的財務和會計職能將由現有團隊暫時管理，同時公司啓動了尋找他的接替者的過渡期以保持穩定。
Altimmune is a clinical-stage biopharmaceutical firm specializing in next-generation peptide-based therapeutics, notably developing pemvidutide for treating obesity and non-alcoholic steatohepatitis (NASH). The company remains committed to advancing its pipeline despite this unexpected setback.
Altimmune是一家專注於下一代基於肽的治療方案的臨床階段生物醫藥公司，尤其是開發用於治療肥胖症和非酒精性脂肪肝（NASH）的pemvidutide。儘管遭受意外挫折，該公司仍致力於推進其新藥研發項目。
ALT Price Action: Altimmune shares were down at market close Wednesday by 15.59% at $6.26, according to Benzinga Pro.
Altimmune的股票價格下跌15.59％，收於6.26美元。
Photo: Via Pixabay.
照片：通過Pixabay。
譯文內容由第三人軟體翻譯。